Eucalyptus oil liquid
Eucalyptus oil is a distilled oil derived from the leaves of the tree Eucalyptus.
Active ingredients:
Eucalyptus oil
No active safety alerts
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Source: MHRA Products DatabaseOGL 3.0
Updated 3 months ago(16 Jan 2026)Safety monitoring data
Yellow Card reports
MHRA
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
EMA
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Eucalyptus oil
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
5 branded products available
Show details
Therapeutically similar medicines
Show details
Acetic acid 0.5% solution
Other
0.5%
Same BNF section
Cade oil 12.5% in Emulsifying ointment
Ointment
12.5%
Same BNF section
Acetic acid 1% solution
Other
1%
Same BNF section
Cade oil 12% / Salicylic acid 4% in Emulsifying ointment
Ointment
12%
Same BNF section
Acetic acid (glacial) 5% solution
Other
5%
Same BNF section
Similarity based on WHO Anatomical Therapeutic Chemical (ATC) classification and NHS BNF section grouping. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Show details
Loading prescribing data...
Clinical guidelines and formulary information
British National Formulary
Eucalyptus oil
BNF
Drug monograph — bnf.nice.org.ukSource: British National Formulary, NICE. Joint Formulary Committee. Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Show details
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & product information
Official product databases and supply status monitoring
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. emc (electronic medicines compendium) is operated by Datapharm Ltd. Shortage information sourced from NHS Specialist Pharmacy Service (SPS), sps.nhs.uk.
Codes for healthcare professionals and prescribing systems
Show details
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF codes from NHS Business Services Authority (NHSBSA).
Active and completed clinical studies from ClinicalTrials.gov
Show details
Searching UK clinical trials...
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
7h
Mechanism
The general consensus is that the exact mechanism of action of eucalyptus oil is…
Food interactions
None known
Human targets
None mapped
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
10 minutes
Common monoterpenoid compound preparations of eucalyptus oil have been observed to be readily absorbed after dermal application, likely due to their lipophilic character .
[A32235]…
[A32235]…
Half-life
90%
Studies have determined a terminal half-life for cineole or eucalyptol (which makes up to as much as 90% of most commonly used cineole-based…
Volume of distribution
90%
Studies have determined a large terminal volume of distribution for cineole or eucalyptol (which makes up to as much as 90% of most commonly…
Metabolism
90%
With in vivo models, eucalyptol or cineole (which make up to as much as 90% of most commonly used cineole-based eucalyptus oils), undergoes oxidation…
Elimination
90%
Studies suggest the route of elimination for cineole or eucalyptol (which makes up to as much as 90% of most commonly used cineole-based eucalyptus…
Clearance
90%
Studies have determined a high clearance rate for cineole or eucalyptol (which makes up to as much as 90% of most commonly used cineole-based…
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
Status:
Approved
Biologic
About this compound
Eucalyptus oil is a distilled oil derived from the leaves of the tree Eucalyptus. It is shown to be effective in reducing pain, swelling, and inflammation via its modulatory effect on the immune response. It is also shown to exhibit antibacterial activity against some bacterial species and cough suppressant actions. Eucalyptus oil can be applied directly to the skin for pain and swelling of respiratory tract mucous membranes, joint pain, genital herpes, and nasal stuffiness.
DrugBank indication
As an active agent, eucalyptus oil has been indicated for relief of the symptoms of catarrhal colds, and/or the relief of the symptoms of minor muscular sprains and cramps .
[L1857]
[L1857]
Also known as(21)
Blue gum leaf oil
Dinkum oil
Eucalypti aetheroleum
Eucalyptus essential oil
Eucalyptus globulus leaf essential oil
Eucalyptus globulus leaf oil
Eucalyptus globulus leaf water
Eucalyptus globulus leaf/twig oil
Dosage forms(45)
Liquid (Respiratory (inhalation)) — 6 %
Oil (Percutaneous; Topical; Transdermal)
Ointment (Respiratory (inhalation); Topical)
Ointment (Respiratory (inhalation))
Spray (Topical)
Oil
Mouthwash (Dental)
Liquid (Respiratory (inhalation)) — 1 %w/v
Drug interactions(731)
Known interactions with other medications. Always consult a healthcare professional.
Cyclosporine
Moderate
Cyclosporine may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level.
Icosapent may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level.
Cefotiam may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level.
Mesalazine
Moderate
Mesalazine may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level.
Cefmenoxime
Moderate
Cefmenoxime may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level.
Cefmetazole
Moderate
Cefmetazole may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level.
Pamidronic acid
Moderate
Pamidronic acid may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level.
Tenofovir disoproxil
Moderate
Tenofovir disoproxil may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level.
Indomethacin
Moderate
Indomethacin may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level.
Cidofovir may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level.
Cefpiramide
Moderate
Cefpiramide may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level.
Ceftazidime
Moderate
Ceftazidime may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level.
Loracarbef
Moderate
Loracarbef may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level.
Cefalotin may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level.
Nabumetone
Moderate
Nabumetone may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level.
Ketorolac may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level.
Tenoxicam may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level.
Celecoxib may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level.
Cefotaxime
Moderate
Cefotaxime may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level.
Tolmetin may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level.
Foscarnet may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level.
Rofecoxib may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level.
Piroxicam may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level.
Methotrexate
Moderate
Methotrexate may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level.
Cephalexin
Moderate
Cephalexin may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level.
Fenoprofen
Moderate
Fenoprofen may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level.
Valaciclovir
Moderate
Valaciclovir may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level.
Valdecoxib
Moderate
Valdecoxib may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level.
Diclofenac
Moderate
Diclofenac may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level.
Sulindac may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level.
Bacitracin
Moderate
Bacitracin may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level.
Amphotericin B
Moderate
Amphotericin B may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level.
Cephaloglycin
Moderate
Cephaloglycin may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level.
Flurbiprofen
Moderate
Flurbiprofen may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level.
Adefovir dipivoxil
Moderate
Adefovir dipivoxil may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level.
Pentamidine
Moderate
Pentamidine may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level.
Etodolac may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level.
Mefenamic acid
Moderate
Mefenamic acid may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level.
Acyclovir may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level.
Naproxen may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level.
Sulfasalazine
Moderate
Sulfasalazine may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level.
Phenylbutazone
Moderate
Phenylbutazone may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level.
Meloxicam may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level.
Carprofen may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level.
Cefaclor may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level.
Diflunisal
Moderate
Diflunisal may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level.
Tacrolimus
Moderate
Tacrolimus may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level.
Ceforanide
Moderate
Ceforanide may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level.
Salicylic acid
Moderate
Salicylic acid may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level.
Meclofenamic acid
Moderate
Meclofenamic acid may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level.
Showing 50 of 731 interactions
Toxicity & overdose
Overdose with eucalyptus oil may result in epigastric burning, nausea and vomiting, dizziness, muscular weakness, mitosis, tachycardia, a sensation of suffocation, cyanosis, ataxia, pulmonary damage, delirium, convulsions, CNS depression, coma. Deaths have been recorded from doses as low as 3.5 ml.
The given oral LD50 for rats is 2480 mg/kg MSDS
The given oral LD50 for rats is 2480 mg/kg MSDS
How it works
Mechanism of action
The general consensus is that the exact mechanism of action of eucalyptus oil is largely unknown at this time but comprises various hypotheses from various studies.
Cineol containing preparations of eucalyptus oil may contain up to 80% (or more) 1,8-cineole [A32243] and is one of the most common types of eucalyptus oil formulations used. As an active agent indicated for relieving certain cold symptoms and/or certain muscular sprains and cramps, it is believed that eucalyptus oil may possess some antimicrobial and anti-inflammatory activities.
Some in vitro studies of human blood monocytes suggest a dose-dependent effect of eucalyptus oil to elicit significant inhibition of multiple cytokines, perhaps in the treatment of airway inflammation [A32244][A32245]. Moreover, other studies in animal models discuss the possibility of eucalyptus oil demonstrating anti-inflammatory and anti-nociceptive effects that potentially account for inhibiting the formation of prostaglandins and cytokines by stimulated monocytes in vitro [A32246][A32247].
Furthermore, additional studies have observed eucalyptus oil anti-viral activity against herpes simplex virus (HSV-1, HSV-2) in cell cultures as well as the demonstration of broad antimicrobial activity of eucalyptus medicinal plant extracts against Alicyclobacillus acidoterretris, Bacillus cereus, E. coli, Enterococcus faecalis, MRSA, Propionibacterium acnes, S. aureus, fungus including C. albicans isolates, Trichophyton mentagrophytes, and other Gram-positive bacteria. Specific activity against periodontopathic bacteria, such as Porphyromonas gingivalis, Actinobacillus actinomycetemcomitans, Fusobacterium nucleatum, Streptococcus mutans, and Streptococcus sobrinus has also been observed [A32250][A32251][A32252][A32253][A32254].
Cineol containing preparations of eucalyptus oil may contain up to 80% (or more) 1,8-cineole [A32243] and is one of the most common types of eucalyptus oil formulations used. As an active agent indicated for relieving certain cold symptoms and/or certain muscular sprains and cramps, it is believed that eucalyptus oil may possess some antimicrobial and anti-inflammatory activities.
Some in vitro studies of human blood monocytes suggest a dose-dependent effect of eucalyptus oil to elicit significant inhibition of multiple cytokines, perhaps in the treatment of airway inflammation [A32244][A32245]. Moreover, other studies in animal models discuss the possibility of eucalyptus oil demonstrating anti-inflammatory and anti-nociceptive effects that potentially account for inhibiting the formation of prostaglandins and cytokines by stimulated monocytes in vitro [A32246][A32247].
Furthermore, additional studies have observed eucalyptus oil anti-viral activity against herpes simplex virus (HSV-1, HSV-2) in cell cultures as well as the demonstration of broad antimicrobial activity of eucalyptus medicinal plant extracts against Alicyclobacillus acidoterretris, Bacillus cereus, E. coli, Enterococcus faecalis, MRSA, Propionibacterium acnes, S. aureus, fungus including C. albicans isolates, Trichophyton mentagrophytes, and other Gram-positive bacteria. Specific activity against periodontopathic bacteria, such as Porphyromonas gingivalis, Actinobacillus actinomycetemcomitans, Fusobacterium nucleatum, Streptococcus mutans, and Streptococcus sobrinus has also been observed [A32250][A32251][A32252][A32253][A32254].
Pharmacodynamics
Lipophilic monoterpene formulations of eucalyptus oil appear to be readily absorbed orally, with a primarily oxidative metabolism that might necessitate induction of the cytochrome P450 enzyme system and subsequent urinary excretion [A32236]. Gastrointestinal absorption of eucalyptus appears to be rapid and may be enhanced by the intake of lipids and milk. 1,8-cineole (which makes up to as much as 90% of most commonly used cineole-based eucalyptus oils) [A32227] has also been found in vitro and in animals to possess cytochrome P450 inducing activity [A32237][A32238][A32239].
Pharmacokinetics
How the body processes this drug — absorption, distribution, metabolism, and elimination
Absorption
Common monoterpenoid compound preparations of eucalyptus oil have been observed to be readily absorbed after dermal application, likely due to their lipophilic character .
[A32235]
Although maximal plasma levels were demonstrated in as short a time period as 10 minutes even with thicker preparations like eucalyptus oil ointments, like many other topically applied agents, the extent of absorption is also likely largely dependent upon additional factors like the size of treated skin area, patient skin condition(s), concentrations of the applied substance, and time of exposure to the substance .
[A32235]
Currently, more data regarding the oral absorption of eucalyptus would be useful, given the relative lack of existing information .
[A32235]
Lipophilic monoterpene compound formulations of eucalyptus oil seems to be readily absorbed orally .
[A32236]
Regardless, there is some data that suggests that the upper part of the gastrointestinal tract has no particularly significant role in the absorption of cineole based eucalyptus oil .
[A32235]
Pulmonary absorption of eucalyptus oil is also possible although little information exists regarding this element at the moment. Nevertheless, 1,8-cineol (which makes up to as much as 90% of most commonly used cineole-based eucalyptus oils) [A32227] appears to be well absorbed via inhalation with peak plasma levels observed reportedly at 18 minutes .
[A32240]
Given the three main constituents from Eucalyptus globulus Labill fruits, the intestinal absorption of macrocarpal A (M-A), macrocarpal B (M-B), and cypellocarpa C (Cy-C) is predominantly via passive diffusion while Cy-C demonstrates some partly ATP-dependent absorption .
[A32242]
[A32235]
Although maximal plasma levels were demonstrated in as short a time period as 10 minutes even with thicker preparations like eucalyptus oil ointments, like many other topically applied agents, the extent of absorption is also likely largely dependent upon additional factors like the size of treated skin area, patient skin condition(s), concentrations of the applied substance, and time of exposure to the substance .
[A32235]
Currently, more data regarding the oral absorption of eucalyptus would be useful, given the relative lack of existing information .
[A32235]
Lipophilic monoterpene compound formulations of eucalyptus oil seems to be readily absorbed orally .
[A32236]
Regardless, there is some data that suggests that the upper part of the gastrointestinal tract has no particularly significant role in the absorption of cineole based eucalyptus oil .
[A32235]
Pulmonary absorption of eucalyptus oil is also possible although little information exists regarding this element at the moment. Nevertheless, 1,8-cineol (which makes up to as much as 90% of most commonly used cineole-based eucalyptus oils) [A32227] appears to be well absorbed via inhalation with peak plasma levels observed reportedly at 18 minutes .
[A32240]
Given the three main constituents from Eucalyptus globulus Labill fruits, the intestinal absorption of macrocarpal A (M-A), macrocarpal B (M-B), and cypellocarpa C (Cy-C) is predominantly via passive diffusion while Cy-C demonstrates some partly ATP-dependent absorption .
[A32242]
Half-life
Studies have determined a terminal half-life for cineole or eucalyptol (which makes up to as much as 90% of most commonly used cineole-based eucalyptus oils) of approximately 7h in brushtail possum (Trichosurus vulpecula) .
[A32227]
[A32227]
Volume of distribution
Studies have determined a large terminal volume of distribution for cineole or eucalyptol (which makes up to as much as 90% of most commonly used cineole-based eucalyptus oils) of 27 l/kg in brushtail possum (Trichosurus vulpecula) .
[A32227]
[A32227]
Metabolism
With in vivo models, eucalyptol or cineole (which make up to as much as 90% of most commonly used cineole-based eucalyptus oils), undergoes oxidation to form hydroxycineole which is excreted as glucuronide .
[L1854]
In rats, 2-hydroxycineole, 3-hydroxycineole, and 1,8--dihydroxycineol-9-oic acid were identified as main urinary metabolites .
[L1854]
After oral administration to brushtail possums, p-cresol, 9-hydroxycineole, and Cineole-9-oic acid were found in urine .
[L1854]
Rabbits given eucalyptol by savage excreted 2-exo- and 2-endo-hydroxycineole in the urine .
[L1854]
The monterpene bicyclic ketone verbenone is a known component in eucalyptus globules .
[A32241]
In one study, this component was observed to be converted to 10-hydroxyverbenone by rat and human liver microsomal cytochrome P450 enzymes, and indicated that CYP2A6 is a principal enzyme in verbenone hydroxylation in humans .
[A32241]
[L1854]
In rats, 2-hydroxycineole, 3-hydroxycineole, and 1,8--dihydroxycineol-9-oic acid were identified as main urinary metabolites .
[L1854]
After oral administration to brushtail possums, p-cresol, 9-hydroxycineole, and Cineole-9-oic acid were found in urine .
[L1854]
Rabbits given eucalyptol by savage excreted 2-exo- and 2-endo-hydroxycineole in the urine .
[L1854]
The monterpene bicyclic ketone verbenone is a known component in eucalyptus globules .
[A32241]
In one study, this component was observed to be converted to 10-hydroxyverbenone by rat and human liver microsomal cytochrome P450 enzymes, and indicated that CYP2A6 is a principal enzyme in verbenone hydroxylation in humans .
[A32241]
Route of elimination
Studies suggest the route of elimination for cineole or eucalyptol (which makes up to as much as 90% of most commonly used cineole-based eucalyptus oils) in brushtail possum (Trichosurus vulpecula), rats, and rabbit subjects as being in the urine .
[A32227]
[A32227]
Clearance
Studies have determined a high clearance rate for cineole or eucalyptol (which makes up to as much as 90% of most commonly used cineole-based eucalyptus oils) of 43 ml/min/kg in brushtail possum (Trichosurus vulpecula) .
[A32227]
[A32227]
Scientific references(22)
Jun Y.S., Kang P., Min S.S., Lee J.M., Kim H.K., Seol G.H.
Effect of eucalyptus oil inhalation on pain and inflammatory responses after total knee replacement: a randomized clinical trial.
Evid Based Complement Alternat Medicine
20132013:502727. doi: 10.1155/2013/502727. Epub 2013 Jun 18
Serafino A., Sinibaldi Vallebona P., Andreola F., Zonfrillo M., Mercuri L., Federici M., Rasi G., Garaci E., Pierimarchi P.
Stimulatory effect of Eucalyptus essential oil on innate cell-mediated immune response.
BMC Immunology
2008 Apr 189:17. doi: 10.1186/1471-2172-9-17
Bachir R.G., Benali M.
Antibacterial activity of the essential oils from the leaves of Eucalyptus globulus against Escherichia coli and Staphylococcus aureus.
Asian Pac Journal Trop Biomed
2012 Sep2(9):739-42. doi: 10.1016/S2221-1691(12)60220-2
McLean S., Boyle R.R., Brandon S., Davies N.W., Sorensen J.S.
Pharmacokinetics of 1,8-cineole, a dietary toxin, in the brushtail possum (Trichosurus vulpecula): significance for feeding.
Xenobiotica
2007 Sep37(9):903-22. doi: 10.1080/00498250701570277
Kohlert C., van Rensen I., Marz R., Schindler G., Graefe E.U., Veit M.
Bioavailability and pharmacokinetics of natural volatile terpenes in animals and humans.
Planta Medicine
2000 Aug66(6):495-505. doi: 10.1055/s-2000-8616
McLean S., Foley W.J.
Metabolism of<i>Eucalyptus</i>Terpenes by Herbivorous Marsupials.
Drug Metabolism Reviews
199729(1-2):213-218. doi: 10.3109/03602539709037582
Jori A., Bianchetti A., Prestini P.E., Gerattini S.
Effect of eucalyptol (1,8-cineole) on the metabolism of other drugs in rats and in man.
European Journal of Pharmacology
19709(3):362-366. doi: 10.1016/0014-2999(70)90236-0
Pass G.J., McLean S., Stupans I., Davies N.
Microsomal metabolism of the terpene 1,8-cineole in the common brushtail possum (Trichosurus vulpecula), koala (Phascolarctos cinereus), rat and human.
Xenobiotica
2001 Apr31(4):205-21. doi: 10.1080/00498250110043535
Miyazawa M., Shindo M., Shimada T.
Roles of cytochrome P450 3A enzymes in the 2-hydroxylation of 1,4-cineole, a monoterpene cyclic ether, by rat and human liver microsomes.
Xenobiotica
200131(10):713-723. doi: 10.1080/00498250110065595
Jager W., Nasel B., Nasel C., Binder R., Stimpfl T., Vycudilik W., Buchbauer G.
Pharmacokinetic Studies of the Fragrance Compound 1,8-Cineol in Humans during Inhalation.
Chemical Senses
199621(4):477-480. doi: 10.1093/chemse/21.4.477
Miyazawa M., Sugie A., Shimada T.
Roles of human CYP2A6 and 2B6 and rat CYP2C11 and 2B1 in the 10-hydroxylation of (-)-verbenone by liver microsomes.
Drug Metabolism and Disposition
2003 Aug31(8):1049-53. doi: 10.1124/dmd.31.8.1049
Yang X.W., Guo Q.M., Wang Y., Xu W., Tian L., Tian X.J.
Intestinal permeability of antivirus constituents from the fruits of Eucalyptus globulus Labill.
in Caco-2 Cell Model
Bioorg Med Chem Lett. 2007 Feb 1517(4):1107-11. doi: 10.1016/j.bmcl.2006.11.021. Epub 2006 Nov 10
Schnitzler P., Schon K., Reichling J.
Antiviral Activity of Monoterpene Components of Essential Oils Against Herpes Simplex Virus.
Antiviral Research
200982(2):A46. doi: 10.1016/j.antiviral.2009.02.103
Juergens U.R., Stober M., Vetter H.
Inhibitory activity of 1,8-cineol (eucalyptol) on cytokine production in cultured human lymphocytes and monocytes.
Pulmonary Pharmacology & Therapeutics
200417(5):281-287. doi: 10.1016/j.pupt.2004.06.002
Juergens U.R., Stober M., Schmidt-Schilling L., Kleuver T., Vetter H.
Differential Effects of Fexofenadine on Arachidonic Acid Metabolism in Cultured Human Monocytes.
Pharmacology
200676(1):40-45. doi: 10.1159/000089263
Santos F.A., Rao V.S.
Antiinflammatory and antinociceptive effects of 1,8-cineole a terpenoid oxide present in many plant essential oils.
Phytotherapy Research
200014(4):240-244. doi: 10.1002/1099-1573(200006)14:4<240::aid-ptr573>3.0.co;2-x
Atta A.H., Alkofahi A.
Anti-nociceptive and anti-inflammatory effects of some Jordanian medicinal plant extracts.
Journal of Ethnopharmacology
199860(2):117-124. doi: 10.1016/s0378-8741(97)00137-2
Sartorelli P., Marquioreto A.D., Amaral-Baroli A., Lima M.E., Moreno P.R.
Chemical composition and antimicrobial activity of the essential oils from two species of Eucalyptus.
Phytother Research
2007 Mar21(3):231-3. doi: 10.1002/ptr.2051
Ahmad I., Beg A.Z.
Antimicrobial and phytochemical studies on 45 Indian medicinal plants against multi-drug resistant human pathogens.
Journal of Ethnopharmacology
200174(2):113-123. doi: 10.1016/s0378-8741(00)00335-4
Takahashi T., Kokubo R., Sakaino M.
Antimicrobial activities of eucalyptus leaf extracts and flavonoids from Eucalyptus maculata.
Lett Applied Microbiology
200439(1):60-4. doi: 10.1111/j.1472-765X.2004.01538.x
Affected organisms(1)
Humans and other mammals
Commercial products(348)
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Eucalyptus oil
DrugBank citations
If you use DrugBank data in your research, please cite the following publications:
Knox C., Wilson M., Klinger C.M., et al
DrugBank 6.
0: the DrugBank Knowledgebase for 2024
Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275
Wishart D.S., Feunang Y.D., Guo A.C., et al
DrugBank 5.
0: a major update to the DrugBank database for 2018
Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082
Show earlier publications
Law V., Knox C., Djoumbou Y., et al
DrugBank 4.
0: shedding new light on drug metabolism
Nucleic Acids Res. 2014 Jan 142(1):D1091-7
Knox C., Law V., Jewison T., et al
DrugBank 3.
0: a comprehensive resource for 'omics' research on drugs
Nucleic Acids Res. 2011 Jan39(Database issue):D1035-41
Wishart D.S., Knox C., Guo A.C., et al
DrugBank: a knowledgebase for drugs, drug actions and drug targets.
Nucleic Acids Research
2008 Jan36(Database issue):D901-6
Wishart D.S., Knox C., Guo A.C., et al
DrugBank: a comprehensive resource for in silico drug discovery and exploration.
Nucleic Acids Research
2006 Jan 134(Database issue):D668-72
Source: go.drugbank.comCC BY-NC 4.0
Updated 27 days ago(8 Mar 2026)